Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the study drug RAD001 can stop or
slow the growth of resectable soft tissue sarcoma. The patient's physical state, their
symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study
will help the research team decide if RAD001 is safe and effective in patients with this
condition. The study drug, RAD001, is made by Novartis Pharmaceuticals Corporation.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute